🇺🇸 Galvus (vildagliptin) in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. General Physical Health Deterioration — 3 reports (17.65%)
  2. Chest Pain — 2 reports (11.76%)
  3. Duodenal Ulcer Haemorrhage — 2 reports (11.76%)
  4. Hypoglycaemia — 2 reports (11.76%)
  5. Myocardial Infarction — 2 reports (11.76%)
  6. Vomiting — 2 reports (11.76%)
  7. Angina Pectoris — 1 report (5.88%)
  8. Arrhythmia — 1 report (5.88%)
  9. Blister — 1 report (5.88%)
  10. Blood Glucose Increased — 1 report (5.88%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Galvus (vildagliptin) approved in United States?

Galvus (vildagliptin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Galvus (vildagliptin) in United States?

Korea University Anam Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.